Trial Profile
Effect of Denosumab and Alendronate on osteoporosis in hemodialysis patients :a randomized controlled trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned number of patients changed from 40 to 80.